Aurexo Therapeutics, a Maryland based biotechnology company, in collaboration with Henry Ford Health, a premier integrated academic healthcare institution based in Michigan, announced today transformative preclinical results demonstrating the potent anti cancer activity of its proprietary bacterial extracellular vesicle (BEV) therapeutic platform (patent pending).

Led by Dr. Javed Siddiqi, PhD, Founder and the Chief Scientific Officer at Aurexo Therapeutics, and Dr. Michael Chopp, Ph.D., Vice Chairman of Research in the Department of Neurology at Henry Ford Health, along with Dr. Zhenggang Zhang and their team at the Neurology Research Laboratory (NRL) has shown that BEV based therapeutics can induce 80–90% tumor regression in human cancer cell lines and in vitro mouse tumor models. Importantly, the BEVs exhibited high selectivity, targeting malignant cells while sparing healthy, non cancerous tissue. Dr. Chopp and his team have generated compelling preclinical data demonstrating the potential of EVs to control tumor progression and metastasis.

“These findings represent a major step forward in the development of next generation biologics,” said Dr. Javed Siddiqi. “Our BEVs demonstrate a unique ability to differentiate cancer cells from normal cells, offering a therapeutic window that is rarely seen in oncology.”

Dr. Chopp emphasized that the teams’ collaborative work shows BEVs could become a powerful new modality in treating aggressive cancers. He added that the strong tumor regression they observed is both compelling and encouraging for future clinical development.

Building on these results, Aurexo Therapeutics is now advancing its BEV program towards triple negative breast cancer (TNBC) — a highly aggressive subtype with limited treatment options and a significant unmet medical need. The company is expanding its mechanistic studies, validating efficacy across additional TNBC models, and preparing for early translational development.

“This collaboration with Henry Ford Health has accelerated our progress in ways that would not have been possible alone,” added Dr. Siddiqi. “We are committed to moving this platform toward first in human studies and ultimately delivering safer, more effective therapies to patients.”

Chief Executive Officer of Aurexo Therapeutics Dr. Imtiaz Mohiuddin added “Through this partnership, Aurexo Therapeutics will gain worldwide commercial rights to Henry Ford Health’s patented EV technologies, in conjunction with our (AT’s) own proprietary innovations. This collaboration has the potential to treat tumor progression and metastasis using EV based advance therapies targeting particularly in triple-negative breast cancer (TNBC). We are extremely excited about the opportunities ahead.”

Dr. Olena Danylyuk, Ph.D., from Henry Ford Health’s Innovations Institute, coordinated all critical meetings and negotiations between the two parties, which resulted in the signing of the licensing and research collaboration agreement.

About Aurexo Therapeutics

Aurexo Therapeutics is a Maryland based biotechnology company developing innovative cancer therapeutics using proprietary bacterial extracellular vesicle (BEV) technology. The company is dedicated to creating highly selective, minimally toxic treatments for some of the most challenging cancers.

For Further Information

Please contact: info@aurexotherapeutics.com